Print Page  Close Window
Meridian Bioscience Granted International ISO Certification to Manufacture Medical Devices for Export

CINCINNATI--(BUSINESS WIRE)--Feb. 3, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has completed all activities required for ISO 13485 registration and final certification.

ISO 13485 is a quality systems approach to managing the processes for manufacturing medical devices to ensure that they conform to customer expectations and governmental standards. More than 75 countries recognize ISO 13485 as the standard of practice for medical device manufacturing. In certain markets, FDA registration alone is no longer sufficient to introduce products to the marketplace.

John A. Kraeutler, President and Chief Operating Officer, stated, "The achievement of ISO 13485 is indicative of Meridian's continuing commitment to compliance with all federal and international quality standards. The successful completion of this process means that our innovative products will continue to be accepted in all of our global markets."

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, urinary and respiratory infections. All Meridian diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents and specialty biologicals along with proteins and other biologicals used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices and diagnostics manufacturers in more than 60 countries around the world. The Company's shares are traded through Nasdaq's National Market, symbol VIVO. Meridian's website address is

CONTACT: Meridian Bioscience, Inc.
John A. Kraeutler, 513-271-3700

SOURCE: Meridian Bioscience, Inc.